Individual absolute changes in liver fat content measured using magnetic resonance imaging-proton density fat fraction at Day 71 (A) and Day 168 (B) post dose for participants with hepatic steatosis receiving repeat doses of 200 mg ARO-ANG3 or placebo.
hepatic steatosis
HEPATIC STEATOSIS
Waterfall plots showing individual absolute changes in liver fat content, measured using magnetic resonance imaging-proton density fat fraction (MRI-PDFF), at post-dose Day 71 (A) and Day 168 (B) for participants with hepatic steatosis receiving repeat doses of 200 mg ARO-ANG3 or receiving placebo.
